Is LMTM the Norwegian Blue of Alzheimer’s Therapy? (2018)

Peer-Reviewed Study · Howard R, Berry A (University College London; Camden and Islington NHS Trust) · March 19, 2018

Howard R et al., 2018-03-19: Published letter by two UK psychiatrists attacking the Wilcock 2018 cohort re-analysis as non-randomised, unmatched and unblinded, and arguing that two large negative trials should end development of the compound.

The authors acknowledge some of the limitations of their analysis, but the overall message of the paper is misleadingly positive about LMTM's potential as an AD therapy.

Howard R et al., 2018-03-19: Published letter by two UK psychiatrists attacking the Wilcock 2018 cohort re-analysis as non-randomised, unmatched and unblinded, and arguing that two large negative trials should end development of the compound. Study type: other.